BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2012

Nov 13, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CATALYST PHARMACEUTICAL PARTNERS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2012-11-05

Reporting Person: BIOMARIN PHARMACEUTICAL INC (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Convertible Promissory Note and Note Purchase Agreement	$0.75	2012-12-08	Common Stock (6666667)		Direct

Footnotes

F1: The Convertible Note will be automatically converted into shares of Common Stock on December 8, 2012 (the "Conversion Date"), which is the 30th day after announcement by Catalyst Pharmaceutical Partners, Inc. (the "Issuer") of top-line data from the Issuer's Phase II(b) clinical trial evaluating the use of CPP-109 (the Issuer's formulation of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction.

F2: The number of shares issuable upon conversion of the Convertible Note is calculated by dividing the aggregate principal amount of the note, $5,000,000 by the "Conversion Price" in effect on the Conversion Date. The Conversion Price is the dollar weighted average price of the Common Stock for the 15 business day period prior to the Conversion Date, multiplied by 0.9; provided, however, that the Conversion price shall not be less than $0.75 per share or more than $2.50 per share. Accordingly, the number of shares beneficially owned by BioMarin Pharmaceutical Inc. may fluctuate from time to time based on the underlying trading price and volume of the Issuer's Common Stock. The number of shares reflected in the table were calculated based on the Conversion Price of $0.75 in effect at the close of trading on November 9, 2012.